Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Massaro

Showing results (411-420 of 422) with videos related to

Pageof 43
Sort By:
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
American Heart Journal|March 20, 2012
Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary syndromes in emergency medical servicesHarry P Selker, Joni R Beshansky, John L Griffith, et al.
The New England Journal of Medicine|November 18, 2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsLaura Mauri, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American Geriatrics Society|July 8, 2020
Identification of Sarcopenia Components That Discriminate Slow Walking Speed: A Pooled Data AnalysisTodd M Manini, Sheena M Patel, Anne B Newman, et al.
The American Journal of Cardiology|May 6, 2014
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial)Harry P Selker, James E Udelson, Joseph M Massaro, et al.
JAMA|March 29, 2012
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trialHarry P Selker, Joni R Beshansky, Patricia R Sheehan, et al.
Circulation|March 31, 2022
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart FailureBarry A Borlaug, John Blair, Martin W Bergmann, et al.
Plos Genetics|March 23, 2011
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traitsElizabeth K Speliotes, Laura M Yerges-Armstrong, Jun Wu, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Association of novel genetic Loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohortsAbbas Dehghan, Qiong Yang, Annette Peters, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 23, 2010
A meta-analysis of four genome-wide association studies of survival to age 90 years or older: the Cohorts for Heart and Aging Research in Genomic Epidemiology ConsortiumAnne B Newman, Stefan Walter, Kathryn L Lunetta, et al.
Pageof 43

Showing results (411-420 of 422) with videos related to

Sort By:
Pageof 43
JAMA Cardiology|September 1, 2018
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical TrialSanjiv J Shah, Ted Feldman, Mark J Ricciardi, et al.
American Heart Journal|March 20, 2012
Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary syndromes in emergency medical servicesHarry P Selker, Joni R Beshansky, John L Griffith, et al.
The New England Journal of Medicine|November 18, 2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsLaura Mauri, Dean J Kereiakes, Robert W Yeh, et al.
Journal of the American Geriatrics Society|July 8, 2020
Identification of Sarcopenia Components That Discriminate Slow Walking Speed: A Pooled Data AnalysisTodd M Manini, Sheena M Patel, Anne B Newman, et al.
The American Journal of Cardiology|May 6, 2014
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial)Harry P Selker, James E Udelson, Joseph M Massaro, et al.
JAMA|March 29, 2012
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trialHarry P Selker, Joni R Beshansky, Patricia R Sheehan, et al.
Circulation|March 31, 2022
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart FailureBarry A Borlaug, John Blair, Martin W Bergmann, et al.
Plos Genetics|March 23, 2011
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traitsElizabeth K Speliotes, Laura M Yerges-Armstrong, Jun Wu, et al.
Circulation. Cardiovascular Genetics|December 25, 2009
Association of novel genetic Loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohortsAbbas Dehghan, Qiong Yang, Annette Peters, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|March 23, 2010
A meta-analysis of four genome-wide association studies of survival to age 90 years or older: the Cohorts for Heart and Aging Research in Genomic Epidemiology ConsortiumAnne B Newman, Stefan Walter, Kathryn L Lunetta, et al.
Pageof 43